RecruitingPhase IIEN originalGlioma (brain cancer)

WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

This phase II trial tests how well the combination of WP1066 and radiation therapy works in treating newly diagnosed glioblastoma. Glioblastoma is difficult to treat effectively because the cells within the tumor vary widely and are controlled by factors within and around the tumor, requiring multiple approaches to treat the tumor. The study drug WP1066 targets a specific pathway, known as STAT3, which is responsible for promoting tumor growth and causing the body's immune system to avoid attacking the tumor. Radiation therapy prevents glioblastoma from growing. Giving WP1066 with radiation therapy may prevent glioblastoma from growing and prolong survival.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Świeżo rozpoznany glejak potwierdzony histologicznie (typ IDH wild-type)
  • Badanie genetyczne IDH wykazujące status wild-type
  • Badanie MGMT wykazujące status niezmutowany
  • Wiek co najmniej 18 lat
  • Ogólny stan zdrowia na poziomie co najmniej 60% w skali Karnofskiego
  • Wystarczająca liczba białych krwinek (≥3,0)
  • Wystarczająca liczba płytek krwi (≥75)
  • Rozpoczęcie leczenia w ciągu 8 tygodni od operacji diagnostycznej mózgu

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
July 22, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (2)

Northwestern University

Chicago, United States

Northwestern Medicine: Warrenville

Warrenville, United States

Trial contact

Amy Heimberger

PRINCIPAL_INVESTIGATOR

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/23/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.